Correct Answer: A. Warfarin
Warfarin causes skin necrosis when initiated acutely in patients with thrombophilia or underlying thrombotic states—a paradoxical prothrombotic phenomenon occurring within 24–72 hours of starting therapy. This occurs because warfarin inhibits synthesis of vitamin K-dependent proteins: factors II, VII, IX, and X, as well as the natural anticoagulants protein C and protein S. Protein C has the shortest half-life (~8 hours), so its levels drop rapidly before the procoagulant factors are depleted. This creates a transient hypercoagulable state, causing microvascular thrombosis in skin and subcutaneous tissues, particularly in areas of high adiposity (breast, abdomen, buttocks, genitalia). In a patient with pre-existing DVT, this risk is substantially elevated. The condition is preventable by bridging therapy with heparin (unfractionated or LMWH) initiated before or simultaneously with warfarin, maintaining anticoagulation until INR reaches therapeutic range (2–3). This is standard practice in Indian hospitals per thromboembolism management guidelines. The image likely shows erythematous, painful lesions with central necrosis—pathognomonic for warfarin-induced skin necrosis.
Why the other options are wrong
B. Dabigatran — Dabigatran is a direct thrombin inhibitor (DOAC) with rapid onset (peak effect 1–2 hours) and does not cause the transient hypercoagulable state seen with warfarin. It does not deplete natural anticoagulants like protein C and protein S. Skin necrosis is not a recognized adverse effect of dabigatran. This option may trap students who confuse all anticoagulants as having similar adverse effect profiles. C. Heparin — Heparin (UFH or LMWH) is actually the protective agent used to prevent warfarin-induced skin necrosis by maintaining anticoagulation during the initial phase when protein C levels are depleted. Heparin does not cause skin necrosis; it causes heparin-induced thrombocytopenia (HIT) as its major adverse effect. This is a classic NBE trap—students may confuse heparin's role as a bridge therapy with a causative agent. D. Rivaroxaban — Rivaroxaban is a factor Xa inhibitor (DOAC) with rapid anticoagulant onset and does not produce the selective depletion of natural anticoagulants that warfarin causes. Like other DOACs, it does not cause the transient hypercoagulable state or skin necrosis. Rivaroxaban is increasingly used in India for VTE management without this complication.
High-Yield Facts
- Warfarin-induced skin necrosis occurs within 24–72 hours due to selective depletion of protein C (half-life 8 hours) before procoagulant factors are depleted.
- Protein C and S depletion creates transient hypercoagulability, causing microvascular thrombosis in adipose-rich areas (breast, abdomen, buttocks).
- Bridging therapy with heparin (UFH or LMWH) is mandatory when initiating warfarin in thrombotic states to prevent skin necrosis.
- Warfarin loading dose should never exceed 5 mg daily in acute thrombosis; slow initiation (2–3 mg) with heparin bridge is standard Indian practice.
- DOACs (dabigatran, rivaroxaban, apixaban) do not cause skin necrosis because they do not selectively deplete natural anticoagulants.
Mnemonics
WARP (Warfarin Adverse Reaction Prevention) Warfarin → Anticoagulant Rebound (protein C depletes first) → Protein C deficiency → Skin necrosis. Always bridge with heparin. PC-First Rule Protein C has shortest half-life (~8 hours), depletes first on warfarin, causing transient hypercoagulability before factors II, VII, IX, X are depleted. Bridge with heparin to prevent this.
NBE Trap
NBE pairs warfarin with "skin necrosis" to test whether students understand the paradoxical hypercoagulable mechanism (protein C depletion) rather than simply knowing warfarin is an anticoagulant. Students may incorrectly choose heparin (the bridge therapy) or DOACs (which don't cause this complication) if they confuse mechanism with clinical use.
Clinical Pearl
In Indian practice, warfarin-induced skin necrosis is now rare because bridging with LMWH (enoxaparin) is routine in DVT management. However, it remains a high-yield NEET PG concept because it tests deep understanding of warfarin's mechanism—not just its anticoagulant effect, but its paradoxical prothrombotic phase. Always suspect this diagnosis in a patient presenting with painful skin lesions within 48–72 hours of warfarin initiation.
_Reference: KD Tripathi Pharmacology Ch. 26 (Anticoagulants); Harrison Ch. 139 (Venous Thromboembolism)_